Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 Study. - Ghafoor A; Roper N; Kim C; Hoang CD; Kesarwala AH; Camphausen KA; Farouq K; Akoth E; Keen C; Szabo E; Bhageri H; Rajan A; et al. (JTO clinical and research reports, 2025)